Videos

Medical experts discuss strategies for educating patients on managing side effects of osimertinib and other EGFR inhibitors, with guidance on recognizing symptoms that warrant contacting their care team.

Profiling a 58-year-old retired construction manager with Stage IV EGFR+ NSCLC, discussing his transition from osimertinib to amivantamab plus chemotherapy, managing side effects, and maintaining hope throughout his treatment journey.

Medical experts discuss strategies for patient education on managing potential adverse events of lorlatinib and other ALK inhibitors, emphasizing what to expect and when to contact the care team.

A 55-year-old mom and high school teacher who received lorlatinib for ALK+ NSCLC with brain metastases.

Panelists discuss how Brandi first noticed symptoms leading to her paroxysmal nocturnal hemoglobinuria (PNH) diagnosis, highlighting the challenges of the initial diagnostic process, and explore the impact of fatigue and brain fog on her daily life. They also address how clinicians assess the severity of these symptoms during consultations and what they indicate about disease progression or treatment needs.

“You can control where you focus your attention,” said Anne M. Reb, PhD, NP, who recently presented on a nurse-led intervention for patients who experience fear of cancer recurrence.

Patients with breast cancer who are of childbearing age may face issues that are accentuated by their age, an expert explained.

Panelists conclude by discussing the future of graft-versus-host disease management, expressing their hopes for the current treatment landscape and potential advancements that could further improve patient outcomes and quality of life.

Panelists discuss how axatilimab, a novel therapy for chronic graft-versus-host disease (cGVHD), functions through a unique mechanism of action compared to other treatments, highlighting its potential role in cGVHD management and presenting key findings from the AGAVE-201 trial that demonstrate its efficacy and safety profile.

Panelists discuss how the current treatment landscape for chronic graft-versus-host disease includes a range of immunosuppressive approaches, from traditional corticosteroids and calcineurin inhibitors to newer approved agents like axatilimab, ruxolitinib, belumosudil, ibrutinib, and abatacept, emphasizing key considerations patients should be aware of when undergoing these therapies.

Panelists discuss how physician assistants educate and empower chronic graft-versus-host disease patients and their caregivers to recognize, report, and manage symptoms effectively, detailing strategies for patient communication, developing personalized symptom management plans, addressing challenging symptoms, and collaborating with the broader healthcare team to ensure comprehensive care.

Panelists discuss how the care team identifies and manages symptoms in chronic graft-versus-host disease patients, particularly those with advanced disease, emphasizing key symptoms to monitor, approaches to symptom identification, and the critical importance of early detection and management for improving patient outcomes.

Panelists discuss how chronic graft-versus-host disease typically progresses in patients requiring third-line treatment and beyond, focusing on severe symptoms, the impact on quality of life, and potential long-term consequences of inadequately managed symptoms.

Panelists discuss how nurse practitioners educate patients about chronic graft-versus-host disease (cGVHD) and its long-term effects, exploring various educational resources and materials such as brochures, apps, websites, and videos that are most effective in supporting patients and their caregivers.

Panelists discuss how chronic graft-versus-host disease (cGVHD) differs from acute GVHD, its main challenges for patients, and its common symptoms and impact on daily life.

Michael Lai, ARNP, explained the mechanism of action of PARP inhibitors for the treatment of patients with prostate cancer.

The Immune Effector Cell Encephalopathy score and keeping a close eye on patients’ symptoms are critical when monitoring for potential ICANS during lymphoma treatment.

A multidisciplinary approach to adverse effect management addresses many needs patients with gynecologic cancers may have while undergoing treatment.

Applying diversity, equity, and inclusion to cancer clinics can help oncology nurses and APPs make an impact on patient care and research.

An expert explained how oncology nurses and APPs should stay informed on the latest genetic mutations that targeted therapies focus in on for non-small cell lung cancer.

An expert discusses recent advancements in breast cancer treatment, focusing on the addition of CDK4/6 inhibitors for high-risk ER-positive, HER2-negative breast cancer.

Meaghan Mooney, B.S.N., RN, OCN, discusses the steps she takes to be an extraordinary healer every day and offers advice for newer oncology nurses.

After reviewing the evidence, nurses switched from heparin-based flushes to all saline flushes for patients disconnecting chemotherapy at home.